Trace Biosciences Receives FDA IND Clearance for First-in-Class Nerve-Specific Imaging Agent LGW16-03
核心洞察
Trace Biosciences (搜索) has received FDA IND clearance for LGW16-03 (搜索), the first nerve-specific fluorescent imaging agent designed to help surgeons visualize peripheral nerves (搜索) in real time during surgery.
The agent selectively binds to peripheral nerves (搜索) and emits near-infrared fluorescent signals, potentially addressing the significant problem of accidental nerve injury (搜索) during surgical procedures.
Phase I clinical studies will begin later this year in orthopedic surgery patients, with plans to expand across multiple surgical indications where nerve injury (搜索) risk is high.
Trace Biosciences (搜索), a clinical-stage biotechnology company developing nerve-targeted imaging agents, has received FDA approval for its Investigational New Drug (IND) application for LGW16-03 (搜索), marking a significant milestone in surgical imaging technology. The clearance enables the company to initiate first-in-human clinical studies evaluating the safety and intraoperative performance of what the company describes as the first nerve-specific fluorescent imaging agent.
Addressing a Critical Unmet Medical Need
LGW16-03 (搜索) is designed to selectively bind peripheral nerves (搜索) and emit a near-infrared fluorescent signal, allowing surgeons to visualize critical nerve structures in real time during surgery even when buried beneath tissues. This technology addresses a significant clinical problem, as accidental nerve injury (搜索) remains a major and under-addressed cause of surgical complications across multiple procedures including prostatectomy, orthopedic surgery, colorectal surgery, and head and neck surgery.
The consequences of nerve injury (搜索) during surgery can be severe and life-altering. According to the company, these injuries can result in chronic pain (搜索), incontinence (搜索), numbness (搜索), sexual dysfunction (搜索), voice loss, or other permanent loss of function – outcomes that profoundly impact patients' quality of life.
"Despite the prevalence and severity of nerve injury (搜索), surgeons still lack approved tools to reliably visualize nerves in real time," said Connor Barth, Ph.D., Co-Founder and CEO of Trace Biosciences (搜索). "We believe LGW16-03 (搜索) has the potential to fundamentally improve surgical safety and patient outcomes."
Clinical Development Strategy
Trace plans to initiate its Phase I clinical study later this year, initially evaluating safety and feasibility in patients undergoing orthopedic surgery. Following successful early clinical studies, the company intends to expand development across multiple surgical indications where nerve injury (搜索) risk is high.
The clinical need for such technology is underscored by current surgical practices. "Surgeons routinely operate near critical nerves with limited to no direct visibility, relying largely on anatomical knowledge and estimated location," said Nirmish Singla, MD, MSCS, FACS, urologic surgeon at Johns Hopkins Medicine (搜索) and clinical advisor to Trace. "A real-time nerve imaging agent like LGW16-03 (搜索) could meaningfully reduce avoidable nerve injuries and change how many common procedures are performed."
Technology Platform and Future Applications
LGW16-03 (搜索), also known as NerveTrace Dx (搜索), represents the first clinical program within Trace's broader nerve-targeted platform. The agent selectively highlights nerve tissue using near-infrared fluorescence that can be detected with surgical imaging systems that are seamlessly integrated into existing surgical workflows.
The company is advancing its platform toward multiple applications beyond intraoperative imaging, including fluorescence-guided surgery, nerve repair or stimulation guidance, and diagnostic imaging. This IND clearance validates more than a decade of scientific work focused on making nerves visible to surgeons, according to Barth.
Company Background
Trace Biosciences (搜索) describes itself as a clinical-stage biotechnology company pioneering nerve-targeted imaging technologies for surgery. Founded by leaders in imaging, chemistry, and translational medicine, the company is developing a new class of small-molecule imaging agents designed to make nerves visible and measurable in clinical settings. The company's stated mission is to make safe, precise surgery a reality by making nerves visible in every operating room.